AstraZeneca Operating Income 2006-2019 | AZN

AstraZeneca annual/quarterly operating income history and growth rate from 2006 to 2019. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • AstraZeneca operating income for the quarter ending September 30, 2019 was $0.757B, a 11.05% decline year-over-year.
  • AstraZeneca operating income for the twelve months ending September 30, 2019 was $3.424B, a 14.29% increase year-over-year.
  • AstraZeneca annual operating income for 2018 was $3.387B, a 7.89% decline from 2017.
  • AstraZeneca annual operating income for 2017 was $3.677B, a 24.99% decline from 2016.
  • AstraZeneca annual operating income for 2016 was $4.902B, a 19.15% increase from 2015.
AstraZeneca Annual Operating Income
(Millions of US $)
2018 $3,387
2017 $3,677
2016 $4,902
2015 $4,114
2014 $2,137
2013 $3,712
2012 $8,148
2011 $12,795
2010 $11,494
2009 $11,543
2008 $8,620
2007 $7,366
2006 $7,131
2005 $6,309
AstraZeneca Quarterly Operating Income
(Millions of US $)
Q3 2019 $757
Q2 2019 $493
Q1 2019 $1,097
Q4 2018 $1,077
Q3 2018 $851
Q2 2018 $763
Q1 2018 $696
Q4 2017 $686
Q3 2017 $1,149
Q2 2017 $925
Q1 2017 $917
Q4 2016 $2,533
Q3 2016 $1,028
Q2 2016 $303
Q1 2016 $1,038
Q4 2015 $1,088
Q3 2015 $1,170
Q2 2015 $923
Q1 2015 $933
Q4 2014 $-349
Q3 2014 $541
Q2 2014 $1,109
Q1 2014 $836
Q4 2013 $-591
Q3 2013 $1,706
Q2 2013 $1,200
Q1 2013 $1,397
Q4 2012 $1,964
Q3 2012 $2,156
Q2 2012 $1,868
Q1 2012 $2,160
Q4 2011 $2,167
Q3 2011 $4,262
Q2 2011 $2,965
Q1 2011 $3,401
Q4 2010 $2,829
Q3 2010 $2,406
Q2 2010 $2,868
Q1 2010 $3,391
Q4 2009 $2,963
Q3 2009 $3,145
Q2 2009 $2,537
Q1 2009 $2,898
Q4 2008 $1,799
Q3 2008 $2,390
Q2 2008 $2,295
Q1 2008 $2,136
Q4 2007 $8,170
Q3 2007 $7,150
Q2 2007 $1,741
Q1 2007 $2,032
Q4 2006 $1,319
Q3 2006 $1,982
Q2 2006 $1,931
Q1 2006 $1,899
Q4 2005 $1,566
Q3 2005 $1,656
Q2 2005 $1,674
Q1 2005 $1,411
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $126.465B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.830B 15.89
Roche Holding AG (RHHBY) Switzerland $263.804B 0.00
Merck (MRK) United States $225.752B 17.49
Pfizer (PFE) United States $211.071B 12.55
Novartis AG (NVS) Switzerland $209.837B 17.71
Novo Nordisk (NVO) Denmark $135.852B 23.42
AbbVie (ABBV) United States $128.953B 10.10
Sanofi (SNY) France $116.718B 14.34
Eli Lilly (LLY) United States $113.939B 21.04
GlaxoSmithKline (GSK) United Kingdom $112.414B 13.62
Bristol-Myers Squibb (BMY) United States $95.965B 13.42
Bayer (BAYRY) Germany $71.769B 10.63
H Lundbeck (HLUYY) Denmark $7.657B 11.05